Johnson & Johnson on Friday became the third company to enter the race to expand the use of its coronavirus vaccine to adolescents. Researchers have begun testing the drug maker’s vaccine in adolescents 12 to 17 years old, the company announced. Johnson & Johnson has been lagging its competitors. Pfizer and BioNTech announced on Wednesday that their coronavirus vaccine is extremely effective in young adolescents, perhaps even more so than in adults. Johnson & Johnson has said it would wait for results from trials in older children before following suit.

Source: New York Times April 02, 2021 14:26 UTC